Womvax I 6mg/400mg Tablet is a combination antiparasitic medication containing Ivermectin 6mg and Albendazole 400mg, indicated for the treatment of a broad spectrum of parasitic infections. Ivermectin acts by binding selectively to glutamate-gated chloride ion channels in nerve and muscle cells of parasites, leading to paralysis and death of the parasite. Albendazole, a benzimidazole derivative, inhibits microtubule synthesis by binding to beta-tubulin, thereby impairing glucose uptake and depleting energy stores in susceptible parasites. This synergistic combination is effective against various helminthic infections including strongyloidiasis, onchocerciasis, ascariasis, trichuriasis, hookworm infections, and neurocysticercosis. Womvax I is also utilized in mass drug administration programs for the control of lymphatic filariasis and other neglected tropical diseases. The tablet is administered orally, with dosage and duration tailored according to the specific parasitic infection and patient profile. It is contraindicated in patients with hypersensitivity to either component, and caution is advised in pregnant or lactating women. Adverse effects are generally mild and transient, including gastrointestinal disturbances, dizziness, and headache. Womvax I 6mg/400mg Tablet offers a potent and convenient therapeutic option for managing complex parasitic infections under medical supervision.